MAPT and Alzheimer disease: Currently, most studies of AD biomarkers in blood have mainly focused on known pathological substrates for the disease, such as amyloid plaques and neurofibrillary tangles, which are respectively composed of the abnormally aggregated amyloid-β peptide (Aβ) and hyperphosphorylated tau (Lewczuk et al., 2018, 2020).